A worldwide Phase 3 trial of a personalized mRNA cancer vaccine showed promise in preventing the recurrence of melanoma [1, 2].
This development represents a potential shift in oncology by using patient-specific genetic data to train the immune system to recognize and destroy remaining cancer cells after surgery.
The trial, conducted by pharmaceutical companies Moderna and Merck, involved approximately 1,000 participants worldwide [1]. Among these participants were 45 patients from New Zealand [1]. The study focused on patients with high-risk melanoma who had already undergone surgery to remove the primary tumor.
Researchers tested whether a personalized mRNA vaccine could extend the period patients remain cancer-free compared to the standard treatment of Keytruda alone [1, 2]. The results reported in August 2024 indicated a significant extension in the time patients lived without the melanoma returning [2].
Unlike traditional vaccines that prevent infectious diseases, this personalized approach targets the specific mutations of an individual's tumor. The vaccine is designed to stimulate a targeted immune response, specifically seeking out proteins unique to the patient's cancer, to prevent the disease from returning.
The global nature of the trial allowed researchers to observe the vaccine's efficacy across diverse populations. By combining the mRNA technology used in COVID-19 vaccines with established immunotherapy, the companies aimed to create a more precise defense against skin cancer recurrence [1, 2].
“A worldwide Phase 3 trial of a personalized mRNA cancer vaccine showed promise in preventing the recurrence of melanoma.”
The success of this Phase 3 trial suggests that personalized medicine—where treatments are tailored to a patient's specific genetic sequence—could become a standard of care for high-risk cancers. If these results are validated and approved by regulators, it would mark one of the first successful applications of mRNA technology for cancer prevention, potentially reducing the reliance on broad-spectrum chemotherapies that often cause systemic toxicity.
